Antistaphylococcal activity of new salicylamide analogues

Antimicrobial resistance is still a serious global threat. Staphylococcus aureus is a common cause of severe infections in health facilities and the community. People with methicillin-resistant S. aureus (MRSA) are estimated to be 64% more likely to die than people with a non-resistant form of the infection [1]. For that reason, the research and development of new active compounds is really needed.

Salicylamides are anti-infectious agents with a wide range of pharmacological effects, such as antiviral, antibacterial, antifungal and anthelminthic [2]. Thus, derivatives of this group are very promising compounds.

A series of newly synthesized complex salicylamide derivatives was tested for their antimicrobial effect against methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus ATCC 29213 as a control and three isolates of MRSA were used. The activity was assessed by the evaluation of minimum inhibitory concentration. Using the microdilution method with subcultivation of aliquots, the minimum bactericidal concentration was determined too. Ciprofloxacin and ampicillin were used as standard antibacterial drugs. Four most promising compounds from the series were chosen and are demonstrated in this contribution.

This study was supported by the institutional support from Ministry of Education, Youth and Sports of the Czech Republic (LO1305).

References:

1. Antimicrobial resistance. World Health Organization Available at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (Oct. 12, 2019).
2. Pospíšilová, Š.; Michnová, H.; Kauerová, T.; Pauk, K.; Kollár, P.; Vinšová, J.; Imramovský, K.; Čížek, A.; Jampílek, J. In vitro activity of salicylamide derivatives against vancomycin-resistant enterococci. Med. Chem. Lett. 2018, 28, 2184-2188.